Pluristem Therapeutics (PSTI) Earning Somewhat Favorable News Coverage, Analysis Finds
Media coverage about Pluristem Therapeutics (NASDAQ:PSTI) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.0748018390077 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration (finance.yahoo.com)
- Should You Buy Pluristem Therapeutics Inc (PSTI)? (finance.yahoo.com)
- Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights (finance.yahoo.com)
- Pluristem Therapeutics Inc. (PSTI) registers a price change of -1.63 … – Stocks Gallery (stocksgallery.com)
- Pluristem Therapeutics (PSTI) & Bio-Path Holdings (BPTH) Financial Review (americanbankingnews.com)
Shares of Pluristem Therapeutics (NASDAQ PSTI) traded up 8.1220% during mid-day trading on Wednesday, hitting $1.3299. 411,368 shares of the stock were exchanged. The firm has a 50-day moving average price of $1.17 and a 200 day moving average price of $1.27. The company’s market capitalization is $129.63 million. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $1.70.
PSTI has been the subject of a number of analyst reports. Maxim Group restated a “hold” rating on shares of Pluristem Therapeutics in a research note on Monday, May 22nd. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 17th. Finally, ValuEngine cut shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $3.19.
TRADEMARK VIOLATION NOTICE: “Pluristem Therapeutics (PSTI) Earning Somewhat Favorable News Coverage, Analysis Finds” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/13/pluristem-therapeutics-psti-earning-somewhat-favorable-news-coverage-analysis-finds.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Stock Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related stocks with our FREE daily email newsletter.